Genomic Health readies for liquid biopsy test launch; Foundation Medicine jumps on liquid biopsy bandwagon amid positive Q4 numbers
In this week's Dx Digest, Genomic Health announced plans to roll out its liquid biopsy test in 2016. Foundation Medicine revealed positive Q4 numbers and talked up its liquid biopsy ambitions. And Qiagen expanded its companion diagnostics prowess through a deal with Array BioPharma.
Dx Digest: Guardant Health scores CE mark, sets out for Europe and South America; Circulogene Theranostics takes liquid biopsy tests to the cloud
In this week's Dx Digest, Guardant Health is teaming up with Synlab Group to distribute its liquid biopsy testing kit in Europe and South America, Med Fusion revealed that it would include Genomic Health's multigene cancer diagnostics in its testing services, and Circulogene Theranostics announced that it would use Station X's cloud-based genome management system to interpret data from its finger-stick cell-free DNA tests.
Invitae already provides testing for at least 15 genetic panels associated with particular diseases for $1,500 each with results coming on average in three weeks. Now it's raised $120 million Series F financing round to build-out its testing infrastructure and expand its global presence.
Nearing its two-year birthday, Invitae announced the closing of a $40 million late-stage financing Tuesday--funds the San Francisco company says will allow it to expand its genetic test offering into global markets.
Contract developer Almac has signed a deal to license its technology to Genomic Health for breast cancer diagnostics, reaping $9 million with the chance for a bigger payday down the road.
Pee on a stick, and then learn whether you have prostate cancer. That's the gist of a new, inexpensive test UC Irvine researchers have developed that would use urine instead of blood to screen for prostate cancer.
Genomic Health launched its prostate cancer diagnostic this week with great fanfare, backed by seven studies including over 1,100 patients. The challenge ahead: convincing men that results telling them they can wait for more drastic and expensive treatment options are to be believed.
Myriad Genetics and Genomic Health lead the bill of companies introducing new prostate cancer diagnostics that promise to change the standard of care, but as the market crowds, payers may balk at the cost while physicians struggle to decide which test is best.
Genomic Health and OncoMed Pharmaceuticals have an agreement to identify new biomarkers useful for future companion diagnostics that would go along with OncoMed's cancer drugs now in development.
With use of molecular diagnostics tests widely expected to skyrocket in the coming decade, UnitedHealth Group is getting increasingly nervous about the trend and looking for ways to manage their use and expense.